The global Next-Generation Biomanufacturing Market size was accounted at USD 19.85 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 9.3% from 2022 to 2030. Biomanufacturing is the production process of biomolecules by utilizing biological services to use in medical & industrial applications. Next-generation biomanufacturing products provide superior services in terms of quality and efficiency compared to first-generation biomanufacturing products.
Major driving factors of the next-generation biomanufacturing market are rising government funding for the development of modern bioprocessing technologies, rapid adoption of advanced technologies, increasing investments by pharma companies to develop & adopt next-generation biomanufacturing products, growing patient population, and increasing awareness among the people regarding the benefits of next-generation biomanufacturing. With the growing demand for drugs and therapies, many biopharmaceutical companies prefer adopting next-generation biomanufacturing services to balance the process design, performance, & efficiency with time and cost. This development is estimated to propel the market growth opportunities over the forecast years. However, complex manufacturing and development procedures and a lack of specialized expertise may hinder the market growth during the estimated timeframe.
The next-generation biomanufacturing market is segmented into medical applications, products, workflow, end-users, and regions. The medical applications segment comprises monoclonal antibodies, hormones, vaccines, recombinant proteins, and other applications. Due to their increasing medical applications, the monoclonal antibodies segment will dominate this market during the forecast years. Based on the products, the market is divided into continuous upstream biomanufacturing products, single-use upstream biomanufacturing products, and downstream biomanufacturing products. The market is classified into upstream and downstream biomanufacturing based on workflow. By end-users, the market is segmented into biopharmaceutical companies, CMOs (contract manufacturing organizations)/CDMOs (contract development and manufacturing organization), and research institutions. Biopharmaceutical companies are estimated to hold a significant market share in the coming years owing to the growing prevalence of chronic diseases and the high demand for protein/drug production. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America led the market due to the robust presence of large biopharmaceutical businesses, the improved infrastructure in biological research, and the rising usage of innovative technologies. The Asia-Pacific market is expected to witness the fastest growth during the forecast period due to the rapid adoption of advanced technologies, rising patient pool, and the high prevalence of chronic diseases. Apart from this, Europe holds the second position in this market regarding revenue share.
Some of the key players operating in the next-generation biomanufacturing market are Applikon Biotechnology BV (Netherlands), bbi-biotech GmbH (Germany), Danaher Corporation (US), Eppendorf AG (Germany), Esco Group of Companies (US), GEA Group Aktiengesellschaft (Germany), Meissner Filtration Products, Inc. (US), Merck KGaA (Germany), PBS Biotech, Inc. (US), Pierre Guérin (France), Sartorius AG (Germany), Shanghai Bailun Biotechnology Co. Ltd. (China), Solaris Biotechnology Srl. (Italy), Thermo Fisher Scientific Inc. (US), ZETA GmbH (Austria), and other.